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LMWHs in the treatment of acute coronary
syndromes
The rupture of an atherosclerotic plaque is the main patho-
physiologic mechanism underlying acute coronary syndromes
[1]. Fissuring plaques expose the flowing blood to sub-
endothelial tissues, and potent stimuli then trigger platelet
aggregation, which is followed by the generation of thrombin
[2]. Thrombin catalyzes the conversion of fibrinogen to fibrin,
is a potent activator of platelet function, and also acts as a
vasoconstrictor [2,3]. Both platelet aggregation and thrombin
generation require an immediate antithrombotic approach to
prevent mortality. The Fifth Consensus Conference on
Antithrombotic Therapy guidelines [4] still recommend
160–325 mg aspirin as the antiplatelet of choice for all
patients presenting with unstable coronary artery disease,
and ticlopidine or clopidogrel as possible alternatives in
unstable angina patients.
In four randomized trials comparing aspirin with placebo in
unstable angina [5–8], the risk of death or myocardial infarc-
tion (MI) was reduced by at least 50% with the regular use of
the antiplatelet agent. Aspirin has also been shown to reduce
vascular mortality (related to coronary artery, cerebral, or
peripheral vascular diseases) and non-fatal reinfarction in the
acute phase of MI [9], as well as long term in post-MI patients
[10].
The glycoprotein IIb/IIIa receptor inhibitors have been shown
to improve the outcomes in patients with unstable angina [11],
and are playing an important role in the treatment of acute
coronary syndromes. The inhibitors are currently recom-
mended for prevention of restenosis in patients undergoing
percutaneous transluminal coronary angioplasty and for
patients presenting with severe unstable angina [4]. Since
thrombin generation is key in the pathogenesis of thrombosis,
additional antithrombotic treatment is necessary to manage
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Abstract
Antithrombotic treatment is of proven importance in patients with acute coronary syndromes. There is
now accumulating evidence from several clinical trials in patients with unstable angina pectoris that the
low molecular weight heparins (LMWHs) are at least as effective as unfractionated heparin. The LMWHs
are easier to use, with the potential to facilitate long-term outpatient treatment. The results of the trials
have actually failed to show any clear advantage, however, of the LMWHs over the standard antiplatelet
treatment, despite the evidence of a sustained hypercoagulability. Potentially, the use of higher doses of
LMWHs could improve the outcomes, but this is as yet unproven and could be associated with
unacceptably increased risk of bleeding. During the acute phase of a stroke, aspirin is the first choice of
antithrombotic drug because it reduces the risk of recurrent stroke. LMWH cannot be recommended as
an antithrombotic agent for the acute treatment of stroke. Prophylactic use of low dose LMWH for the
prevention of venous thromboembolism should be considered in every patient with a stroke.
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acute coronary ischemia. Unfractionated heparin is still the
standard antithrombotic, recommended to be administered for
at least 48 hours, in patients with unstable coronary artery
disease. It should be given intravenously with an initial bolus of
75 U/kg followed by a continuous infusion of approximately
1250 U/hour to obtain an activated partial thromboplastin time
at 1.5–2.0 times control values [4]. Its efficacy in reducing the
rate of mortality and acute MI following an episode of unstable
angina, in particular when combined with aspirin, has been
conclusively proven by several randomized trials [12].
However, unfractionated heparin has a number of limitations
directly related to its pharmacokinetic and pharmacodynamic
properties. Its anticoagulant effect is unpredictable and varies
considerably among patients [13]. To ensure a more rapid
therapeutic response, heparin must therefore be given intra-
venously. This requires hospitalization and frequent monitor-
ing to optimize its effect [14]. Dose adjustments can be
cumbersome and, frequently, heparin dosages are subopti-
mal. Unfractionated heparin has further effects on hemostasis
such as the inhibition of platelet aggregation and the increase
in vessel wall permeability, which can significantly enhance its
potential to cause bleeding complications [15]. Finally,
heparin-induced thrombocytopenia, a complication that can
lead to serious consequences and that occurs in as many as
3% of treated patients, should always be taken into account
for patients treated with unfractionated heparin [16].
LMWHs (on average, one-third the molecular size of standard
heparin) offer a number of pharmacokinetic and pharmacody-
namic advantages over heparin (Tables 1 and 2). Their
antithrombotic response is more predictable and, as a conse-
quence, laboratory monitoring of therapy is not required [17].
In addition to good bioavailability following subcutaneous
injections, LMWHs also have much longer half-lives than
unfractionated heparin [18]. These advantages mean that an
adequate and persistent anticoagulant effect can be achieved
with LMWHs administered by once-daily or twice-daily subcu-
taneous injections at fixed or weight-adjusted doses.
Although the LMWHs in clinical use have many similarities,
they also differ from one another in a number of ways
(Table 3). They have different molecular weight distribution
profiles, small differences in their specific activities
(anti-Xa:anti-IIa activities), different rates of plasma clear-
ance, and some differences in their recommended dosage
regimens [17]. The potential advantages over unfractionated
heparin, and the positive results of the clinical studies using
LMWH in the prevention and treatment of venous thrombo-
embolism have led to the evaluation of these newer com-
pounds in all these clinical settings. Large-scale clinical trials
have recently been carried out to evaluate LMWHs (in partic-
ular, nadroparin, dalteparin and enoxaparin) in the clinical
setting of unstable angina and non-Q-wave MI.
Clinical trials assessing LMWHs in unstable
angina and non-Q-wave MI
Nadroparin
The first comparison between a LMWH and unfractionated
heparin in patients with unstable angina was in a small study
published in 1995 by Gurfinkel et al [19] (Table 4). It was a
single blind trial in which 211 patients were randomized to
twice-daily treatment with either weight-adjusted nadroparin
(214 UIC/kg anti-Xa) and aspirin (200 mg/day), intravenous
standard heparin (adjusted for the activated partial thrombo-
plastin time) and aspirin, or aspirin alone. Patients with non-
Q-wave MI were excluded. After 5–7 days, when the
antithrombotic treatment was discontinued, there was a
reduction greater than 50% in the rate of recurrent angina, as
well as a significant decrease in the rates of silent ischemia
Table 1
Comparison between heparin and low molecular weight
heparin (LMWH) size and anticoagulant activity
Heparin LMWH
Mean molecular weight 12,000–15,000 4000–6500
Saccharide units (mean) 40–50 13–22
Anti-Xa : anti-IIa activity 1:1 2:1–4:1
Table 2
Comparison of pharmacokinetic properties of heparin and low
molecular weight heparin (LMWH)
Heparin LMWH
Bioavailability at low doses (%) 30 90
Bioavailability at high doses (%) 90 90
Elimination
Low doses Cellular uptake  Renal 
(saturable) (non-saturable)
High doses Renal Renal
Half-life Dose dependent  Dose independent 
(30 min–4 h) (2–4 h)
Table 3
The anticoagulant profiles, molecular weights, and plasma
half-lives of the commercial low molecular weight heparins
discussed
Molecular Plasma
Anti-Xa:anti-IIa weight  half-life
Agent ratio (saccharide units) (min)
Enoxaparin 2.7:1 4500 120–180
Dalteparin 2.0:1 5000 119–139
Nadroparin 3.2:1 4500 132–162c
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and the need for revascularization in the group receiving
nadroparin, as compared with the other two groups. The
major bleeding rate was comparable between the LMWH
and unfractionated heparin. Minor bleedings during the acute
phase were significantly less with nadroparin as compared
with unfractionated heparin.
Dalteparin
The second LMWH to be tested in this setting was dal-
teparin. The Fragmin During Instability in Coronary Artery
Disease (FRISC) study [20] (Table 4) was a double blind,
randomized trial that compared dalteparin (120 IU/kg, twice
daily for the first 6 days) and aspirin (75 mg/day) with aspirin
alone in 1506 patients. After 6 days of treatment, patients ini-
tially randomized to the LMWH were switched to a single,
lower, fixed dose (7500 IU) to be continued for up to 45 days.
This was the first attempt to reduce long-term ischemic
events with an antithrombotic agent. The rationale was based
on the observation that, in unstable coronary artery diseases,
a persistent hypercoagulable state is present for several
months after the acute event [21,22]. Moreover, a raised
event rate for at least 6–12 weeks after the acute episode
was clinically observed [8]. During the first 6 days of treat-
ment, dalteparin reduced the risk of death or MI in unstable
angina patients with a reduction in relative risk of 63%. The
frequency of death or MI after 40 and 150 days, the sec-
ondary endpoints of the study, did not statistically differ from
that of the aspirin alone group.
A second trial with dalteparin was the Fragmin in Unstable
Coronary Artery Disease (FRIC) study [23] (Table 4), which
was designed in two phases. During the acute phase, 1482
patients received, in an unblinded fashion, the LMWH
(120 IU/kg twice daily) or intravenous unfractionated heparin
at the common doses (intravenous 5000 IU bolus followed by
continuous infusion aimed to achieve a target aPTT of 2.0)
with aspirin. The two compounds were found to be equivalent
both in efficacy and safety. The second phase was double
blinded, and patients were randomized to continue antithrom-
botic treatment with one, daily fixed dose of dalteparin
(7500 IU) or with placebo for up to 45 days from the inclusion
in the study. As in the FRISC study, the prolonged treatment
with dalteparin did not confer any additional benefit over
aspirin alone. In both studies, major bleeding rates were com-
parable between dalteparin and unfractionated heparin (FRIC)
and between dalteparin and placebo (FRISC) during the acute
phase, as well as during the prolonged treatment phase.
Latest trials
A new LMWH, enoxaparin, then appeared in the contest. The
Efficacy and Safety of Subcutaneous Enoxaparin in non-Q-
wave Coronary Events (ESSENCE) trial, with 3171 patients
with unstable angina and non-Q-wave MI enrolled, is the
largest trial so far conducted [24] (Table 4). It was designed
to compare a fixed dose of subcutaneous enoxaparin
(1.0 mg/kg twice daily) plus aspirin (100–325 mg/day) with
intravenous unfractionated heparin adjusted to the activated
Available online http://cvm.controlled-trials.com/content/2/5/233
Table 4
Randomized trials of low molecular weight heparin (LMWH) in unstable angina and non-Q-wave myocardial infarction (MI)
Treatment
duration Follow-up LMWH Control
Study LMWH n Primary outcome (days) (days) (%) (%) P
Gurfinkel et al,  Nadroparin 211 MI, death, recurrent angina, urgent  5–7 5–7 22 59* 0.00001
1995 [19] revascularization, major bleeding 63† 0.00001
FRISC, 1996 [20] Dalteparin 1506 MI — death 35–45 6 1.8 4.8‡ 0.001
40 8.0 10.7‡ 0.07
150 14 15.5‡ 0.41
FRIC, 1997 [23] Dalteparin 1506 MI/death/recurrent angina 6 6 9.3 7.6† 0.33
45 6–45 12.3 12.3‡ 0.96
ESSENCE, 1997 [24] Enoxaparin 3171 MI/death/recurrent angina 2–8 14 16.6 19.8† 0.02
30 19.8 23.3† 0.02
6/14 days
FRAXIS, 1999 [28] Nadroparin 3468 MI/death/refractory angina 6 or 14 6 13.8/15.8 14.9† ns
14 17.8/20.0 18.1† ns
90 22.3/25.2 22.2† ns
FRISC II, 1999 [26] Dalteparin 2267 Death — MI 90 30 3.1 5.9‡ 0.002
90 6.7 8.0‡ 0.17
TIMI 11b, 1999 [27] Enoxaparin 3910 Death/MI/urgent revascularization 8 or 43 14 14.2 16.6† 0.03
43 17.3 19.6† 0.049
ns, Not significant. * Aspirin, † heparin, ‡ placebo.partial thromboplastin time plus aspirin. Antithrombotic treat-
ment was administered for up to 8 days and for a median of
2.8 days. At 14 days, the primary endpoint of the study, the
composite risk of death, MI or recurrent angina was signifi-
cantly lower in patients assigned to enoxaparin than in those
receiving unfractionated heparin, with a 16.2% reduction in
risk. This reduction was maintained at 30 days. Major bleed-
ing rates were comparable between enoxaparin and unfrac-
tionated heparin, whereas the rate of minor bleeding was
significantly increased in the enoxaparin group as compared
with heparin. At 1 year, the early benefits of enoxaparin over
unfractionated heparin in the primary endpoint were still sus-
tained [25]. Nevertheless, even in the enoxaparin group, the
primary endpoint was doubled from 16.6% after 14 days to
32.0% after 1 year, thus confirming the need for an improved
antithrombotic strategy in the long term.
The FRISC II study specifically addressed the question on the
benefits of the long-term treatment, evaluating dalteparin in
patients with unstable coronary disease [26] (Table 4). All
patients received at least 5 days of treatment with dalteparin
(120 IU/kg twice daily) and were then randomized to placebo,
or to continue dalteparin, for a total of 3 months (5000 or
7500 IU, according to body weight, twice daily). Aspirin was
prescribed to all patients. Once more, the results obtained
with the long-term treatment were somewhat unsatisfactory.
There was a reduction in the risk of death, MI, and revascular-
ization at 30 days, and a non-significant decrease in the com-
posite endpoint of death or MI at 3 months, but no benefits at
all at 6 months. During the extended treatment period, both
major and minor bleeding episodes were increased in the dal-
teparin group.
Following the convincing results obtained in the acute phase,
enoxaparin was then evaluated in the long-term treatment.
Patients in the Thrombolysis in Myocardial Infarction (TIMI)
11b trial [27] (Table 4) were randomized to unfractionated
heparin administered for a minimum of 72 hours, or to thera-
peutic doses of the LMWH (initially a 30 mg bolus, followed
by 1.0 mg/kg every 12 hours) given for up to 8 days and fol-
lowed by a once-daily fixed dose (40–60 mg twice daily) for
an additional 35 days. Almost 4000 patients were included in
the trial. As in the ESSENCE trial, at 14 days, the primary
endpoint of death, MI, and the need for revascularization were
significantly reduced by enoxaparin with a relative risk reduc-
tion of 15%. At 43 days the early benefit was significantly
maintained (relative risk reduction, 12%), but no additional
benefit was produced. As regards safety, there was no differ-
ence in major bleeding events during the acute phase, but
there was a significant increase in the long-term phase when
enoxaparin was compared with placebo.
Finally, the Fraxiparine in Ischaemic Syndrome (FRAXIS)
study [28] (Table 4) was the first large trial to assess
nadroparin in patients with unstable angina after the results of
the study by Gurfinkel et al. Standard therapeutic doses of
unfractionated heparin administered for 6 days were com-
pared with either 6 or 14 days of nadroparin (100 anti-
Xa U/kg bolus followed by 100 anti-Xa U/kg twice daily). The
study enrolled 3468 patients, all of whom received aspirin
concomitantly. The triple, primary endpoints of death, MI, and
refractory angina were not different among the three groups
after 6 and 14 days, but were significantly worse at 3 months
in the group treated with nadroparin for 14 days. Major bleed-
ing rates were also increased in this group at 14 days as well
as at 3 months.
Clinical trials assessing LMWH in acute MI
Among studies that evaluated the use of antithrombotics in
patients with acute MI, two were designed to evaluate
LMWH: the Fragmin in Acute Myocardial Infarction (FRAMI)
study [29], and a study by Glick et al [30]. The FRAMI study
[29] was a randomized, double blind trial of 776 patients
comparing weight-adjusted subcutaneous dalteparin adminis-
tered twice daily against placebo. Treatment was given for up
to 11 days, together with aspirin and streptokinase in the
acute phase. After 3 months, the rate of left ventricular
thrombi was significantly lower in the LMWH group, as well
as the combined rate of left ventricular thrombosis and arter-
ial embolism. There was also a non-significant trend in favor
of dalteparin in the reinfarction rate, but the occurrence of
both major and minor bleedings was significantly higher.
In the study by Glick et al [30], the use of the LMWH was dif-
ferent. The authors randomized 103 patients to a prophylactic
dose of enoxaparin (40 mg daily), or to no treatment, for
25 days in an unblinded study. In the acute phase, all patients
received streptokinase, unfractionated heparin, and aspirin.
After 6 months, there was a significantly lower reinfarction
rate and a trend toward a lower angina rate in favor of enoxa-
parin. No major bleedings were observed and minor bleed-
ings were only detected in the no treatment group.
Persisting dilemmas
There is now accumulating evidence from the results of the
recent clinical trials to affirm that the LMWHs are at least as
effective as the standard treatment (unfractionated heparin).
As a consequence, clinical guidelines [31,32] recommend
the use of all LMWHs as a class. Following the data of the
ESSENCE trial and of the TIMI 11b trial, enoxaparin was the
only LMWH to show superiority over unfractionated heparin.
In all settings, the different biochemical properties of the
compounds have always required individual tests before any
potential approval for clinical use, but how this difference
can be determined on such results is not clear. Differences
in study designs or the ‘play of chance’ have been pro-
posed. Differences in the quality of the management of
intravenous unfractionated heparin therapy among centers
have also been observed. This is a reminder of how prob-
lematic it can be to obtain good quality unfractionated
heparin dose-adjusted therapy in the routine clinical prac-
tice of an average hospital.
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unfractionated heparin and LMWH are, at the end, substan-
tially equivalent. This equivalence can be extended to all dif-
ferent LMWH. The LMWHs, however, have the advantage of
easier use. The results of specifically addressed trials have so
far actually failed to show any clear advantage of the LMWHs
over the standard antiplatelet treatment, despite the evidence
of a sustained hypercoagulability. The use of higher doses
might improve the outcomes, but the consequent increased
risk of bleeding is a high price to pay.
Finally, potential markers of a poor outcome to identify sub-
groups of patients most likely to benefit from the long-term
therapy would be of great help. From a substudy of the
FRISC trial, a statistically significant protective effect of dal-
teparin, during the long-term treatment phase, was found in
the subgroup of patients with troponin T levels ≥0.1 µg/l
(event rate reduced from 14.2% with placebo to 7.4% with
dalteparin), whereas patients with troponin T levels <0.1 µg/l
did not benefit from the therapy with the LMWH [33]. The
troponin-T-negative patients showed a lower rate of adverse
events independent of the treatment received (4.7% with
placebo and 5.7% with dalteparin). This suggests that
troponin T levels measured on admission could identify
patients at higher risk for whom the prolonged treatment
might be beneficial. Also, another substudy from the
ESSENCE trial [34] identified Von Willebrand factor, a
phase-reactant protein, as a possible independent predictor
of the severity of the disease that could be useful to deter-
mine a more appropriate treatment strategy.
LMWHs in the treatment of acute stroke
Ischemic stroke, although heterogeneous in nature, shares a
pathophysiological basis that is similar to the underlying
mechanisms of acute coronary syndromes. While established
methods for prevention of ischemic stroke exist — treatment
with antiplatelets, oral anticoagulants or carotid endarterec-
tomy [35] — there is no established specific anticoagulant
treatment for acute episodes that has shown reduction in
mortality or improvement in functional status [36,37]. Antico-
agulant agents, including heparin, have been given for
decades, but their benefits are unproven and their use there-
fore remains controversial [38–40]. If anticoagulants are used
in patients with stroke, there is the worry of increasing the
likelihood of intracranial hemorrhage, thereby worsening the
prognosis. Data from the large, randomized International
Stroke Trial showed that there was a significantly increased
risk of both intracranial and extracranial hemorrhage with
unfractionated heparin, even when given at low doses
(5000 IU subcutaneously twice daily) [41]. LWMH with less
potential for hemorrhage would, in theory, have some advan-
tages for the treatment of stroke, and for the prevention of
deep vein thrombosis (DVT) and pulmonary embolism (PE).
Finally, in the National Institute of Neurological Disorders and
Stroke (NINDS) Recombinant Tissue Plasminogen Activator
Stroke Study, a statistically and clinically significant improve-
ment in functional outcome was found when using throm-
bolytic therapy in patients with acute stroke who presented
within a narrow time window of 3 hours after the start of
symptoms [42,43].
Clinical trials assessing LMWH in patients
with acute stroke
The Hong Kong Fraxiparine in Stroke Study (FISS) was the
first investigation comparing nadroparin in a low dose
(4100 IU once daily) or a high dose (4100 IU twice daily;
comparable with doses used in patients with DVT) for a
period of 10 days versus placebo [44]. Patients with acute
ischemic strokes of all degrees of severity, within 48 hours
of the onset of symptoms, were included. The primary end-
point consisted of ‘poor outcome’, which was defined as
death or dependency with respect to daily activities during
the 6 months after randomization. This endpoint was
reached in 45% of patients in the high dose LMWH group,
52% in the low dose LMWH group, and 65% in the
placebo group. There was a highly significant dose-depen-
dent effect among the three study groups in favor of the
LMWH (P < 0.005 by chi-square test for trend). In this
study, there was no significant difference between the
treated patients and those patients given placebo in rates of
hemorrhagic transformation of the infarct. After this positive
outcome of the FISS, several other studies have been per-
formed, including the Trial of ORG 10172 in Acute Stroke
Treatment (TOAST) [45] and the Fraxiparine in Stroke Trial
(FISS bis) [46].
In the recent Heparin in Acute Embolic Stroke Trial (HAEST)
[47], LMWH was compared with aspirin. The HAEST has
compared the effect of the LMWH dalteparin (100 IU twice a
day) versus that of aspirin (160 mg per day), over 14 days, in
patients with atrial fibrillation who suffered an acute ischemic
stroke within 30 hours of onset. The primary endpoint in this
study was recurrent stroke during the first 14 days. The data,
however, did not show a benefit of the LMWH with regard to
this endpoint.
The overall conclusion from these three studies is that
none has been able to reduplicate the benefit seen in the
FISS on the overall outcome of patients with acute
ischemic stroke. Clinicians may still want to use heparin for
prevention of DVT and PE, for which patients with stroke
are at high risk. Systemic reviews have clearly demon-
strated that anticoagulant therapy significantly reduced the
risk for DVT from 44 to 10% (odds reduction, 80%) [48].
There was also a significant reduction in the odds of PE
with anticoagulants but, as the authors noted, the absolute
benefit was rather small with only four PEs avoided per
1000 patients treated [48]. In view of these data, the use
of low dose LMWH could be considered in a patient with
an acute stroke.
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The authors conclude that, for the acute phase of a stroke,
aspirin is the first choice of antithrombotic drug because it
reduces the risk of recurrent stroke. LMWH cannot be rec-
ommended as an antithrombotic agent for the acute treat-
ment of stroke. Prophylactic use of low dose LMWH for the
prevention of venous thromboembolism could be considered
in every patient. Finally, long-term oral anticoagulant treatment
should be given to patients with atrial fibrillation after stroke
or transient ischaemic attack (target range International Nor-
malized Ratio, 2.0–3.0) but the time to start this medication is
as yet uncertain.
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